Ranch Capital Advisors Inc. Has $682,000 Stake in Danaher Co. (NYSE:DHR)

Ranch Capital Advisors Inc. boosted its holdings in shares of Danaher Co. (NYSE:DHR) by 8.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,727 shares of the conglomerate’s stock after acquiring an additional 212 shares during the quarter. Ranch Capital Advisors Inc.’s holdings in Danaher were worth $682,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the business. Tsfg LLC grew its holdings in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the last quarter. nVerses Capital LLC acquired a new position in Danaher during the 2nd quarter valued at $25,000. CarsonAllaria Wealth Management Ltd. bought a new stake in Danaher in the 2nd quarter valued at $25,000. Cape Investment Advisory Inc. acquired a new stake in Danaher in the 4th quarter worth $25,000. Finally, Redmont Wealth Advisors LLC bought a new position in shares of Danaher during the 1st quarter worth about $30,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on DHR. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Bank of America upped their target price on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. TD Cowen upped their price objective on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Royal Bank of Canada restated an “outperform” rating and set a $300.00 target price on shares of Danaher in a research report on Friday, September 6th. Finally, Stifel Nicolaus boosted their target price on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $278.94.

Danaher Price Performance

Shares of NYSE DHR opened at $276.43 on Friday. The business has a 50-day moving average of $267.10 and a 200-day moving average of $257.03. The stock has a market capitalization of $204.75 billion, a price-to-earnings ratio of 46.85, a PEG ratio of 4.48 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same quarter last year, the company posted $2.05 EPS. As a group, sell-side analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Linda Filler sold 3,928 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the transaction, the director now owns 41,149 shares in the company, valued at $11,501,145.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock valued at $11,042,433 over the last 90 days. 11.10% of the stock is owned by insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.